Neoadjuvant Therapy With Herceptin and Taxol for Stage II/III Breast Cancer
Patients will receive Herceptin intravenously once weekly for 12 weeks, and Taxol
intravenously every 3 weeks (week 1, week 4, week 7 and week 10).
After 12 weeks of treatment, breast surgery will be performed (either a lumpectomy or a
Once patients have recovered from the surgery, they will receive adriamycin and cytoxan
every 3 weeks for 4 cycles (12 weeks total).
After Herceptin and Taxol therapy, tumor assessment will be performed along with an
echocardiogram and mammogram.
At the time of surgery, re-assessment of the tumor will be done.
Blood work will be performed on day one of each chemotherapy cycle.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the response of HER2-positive breast cancer to treatment with Herceptin and Taxol prior to surgery
Harold Burstein, MD, PhD
Dana-Farber Cancer Institute
United States: Institutional Review Board
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|